Literature DB >> 19946240

Time for new indications for statins?

Maciej Banach1, Dimitri P Mikhailidis, Sverre E Kjeldsen, Jacek Rysz.   

Abstract

The role of statins in the treatment and prevention of cardiovascular diseases, such as coronary artery disease, acute coronary syndromes, diabetes or stroke is well established. However, there are still some questions regarding the role of statins in patients with heart failure, hypertension, atrial fibrillation and chronic kidney disease (CKD). This editorial review discusses the current evidence regarding the use of statins in patients with hypertension (with or without dyslipidemia) or CKD. We need new large randomized clinical trials to confirm the potentially beneficial positive results obtained so far.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19946240

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN： 1234-1010


  26 in total

1.  Blood lipid levels, lipid-lowering medications, and the incidence of atrial fibrillation: the atherosclerosis risk in communities study.

Authors:  Faye L Lopez; Sunil K Agarwal; Richard F Maclehose; Elsayed Z Soliman; A Richey Sharrett; Rachel R Huxley; Suma Konety; Christie M Ballantyne; Alvaro Alonso
Journal:  Circ Arrhythm Electrophysiol       Date:  2012-01-06

2.  Influence of co-existing atrial fibrillation on the efficacy of atorvastatin treatment in patients with dilated cardiomyopathy: a pilot study.

Authors:  Agata Bielecka-Dabrowa; Jan Henryk Goch; Jacek Rysz; Marek Maciejewski; Ravi Desai; Wilbert S Aronow; Maciej Banach
Journal:  Lipids Health Dis       Date:  2010-02-23       Impact factor: 3.876

Review 3.  Medication management of chronic heart failure in older adults.

Authors:  Kannayiram Alagiakrishnan; Maciej Banach; Linda G Jones; Ali Ahmed; Wilbert S Aronow
Journal:  Drugs Aging       Date:  2013-10       Impact factor: 3.923

4.  The impact of statin therapy on long-term cardiovascular outcomes in an outpatient cardiology practice.

Authors:  Hoang M Lai; Wilbert S Aronow; Anthony D Mercando; Phoenix Kalen; Harit D Desai; Kaushang Gandhi; Mala Sharma; Harshad Amin; Trung M Lai
Journal:  Med Sci Monit       Date:  2011-12

5.  Lipid-lowering therapies and achievement of LDL-cholesterol targets.

Authors:  Manfredi Rizzo; Maciej Banach; Giuseppe Montalto; Dimitri P Mikhailidis
Journal:  Arch Med Sci       Date:  2012-09-08       Impact factor: 3.318

6.  Malignancy-associated dyslipidemia.

Authors:  Agata Bielecka-Dąbrowa; Simon Hannam; Jacek Rysz; Maciej Banach
Journal:  Open Cardiovasc Med J       Date:  2011-02-24

7.  Lipids, blood pressure, kidney - what was new in 2011?

Authors:  Marcin Barylski; Jolanta Małyszko; Jacek Rysz; Michał Myśliwiec; Maciej Banach
Journal:  Arch Med Sci       Date:  2011-12-30       Impact factor: 3.318

8.  Hypotensive effect of atorvastatin in hypertensive patients: the association among flow-mediated dilation, oxidative stress and endothelial dysfunction.

Authors:  Agnieszka M Tycinska; Jacek Janica; Barbara Mroczko; Wlodzimierz J Musial; Robert Sawicki; Bozena Sobkowicz; Karol Kaminski; Urszula Lebkowska; Maciej Szmitkowski
Journal:  Arch Med Sci       Date:  2011-12-30       Impact factor: 3.318

9.  Are we getting to lipid targets in real life?

Authors:  Niki Katsiki; Dimitri P Mikhailidis; Vasilis G Athyros; Apostolos I Hatzitolios; Asterios Karagiannis; Maciej Banach
Journal:  Arch Med Sci       Date:  2010-10-26       Impact factor: 3.318

10.  The influence of atorvastatin on parameters of inflammation left ventricular function, hospitalizations and mortality in patients with dilated cardiomyopathy--5-year follow-up.

Authors:  Agata Bielecka-Dabrowa; Dimitri P Mikhailidis; Manfredi Rizzo; Stephan von Haehling; Jacek Rysz; Maciej Banach
Journal:  Lipids Health Dis       Date:  2013-04-08       Impact factor: 3.876
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.